Key result
Preoperative IV heparin is linked to a reduced antithrombin III activity-to-antigen ratio before CABG.
Why the study?
Does preoperative intravenous heparin therapy affect antithrombin III levels and function in patients undergoing coronary artery bypass grafting?
Observational (n=30)
No
Does preoperative intravenous heparin therapy affect antithrombin III levels and function in patients undergoing coronary artery bypass grafting?
Preoperative heparin exposure alters the functional-to-quantitative ratio of antithrombin III, which may contribute to heparin resistance during cardiopulmonary bypass.
Answers are grounded in this paper and cite their sources.
Heparin-associated antithrombin ratio changes may signal resistance risk in CABG; hypothesis-generating and should not yet change practice.
Resistance to the anticoagulation action of sodium heparin during cardiopulmonary bypass is a serious concern and a poorly understood phenomenon. In the majority of cases, the desired prolongation of the activated clotting time (ACT) is achieved by administration of additional heparin. A patient's previous exposure to heparin has been suggested as the cause of this clinical dilemma. The administration of fresh frozen plasma to patients who demonstrated a heparin resistance have been shown to produce a normalization of their heparin/ACT dose response curve and a decrease in total heparin requirements during cardiopulmonary bypass. These results could be an indication of a deficiency of a component in patient's plasma. This study was designed to compare antithrombin III (AT III) in two patient populations. Group A consisted of 15 patients receiving intravenous heparin therapy prior to cardiopulmonary bypass for greater than 24 hours. Population B included 15 patients who had not been exposed to heparin therapy preoperatively. All patients were candidates for coronary artery bypass grafting. The quantitative assay utilized the Loyal Rocket Immunoelectrophoresis Technique and the qualitative assay was determined by the AT III Anti-10A Activity Assay. Two sample t-test analyses of variance revealed no statistical significance (p<0.05) between the two populations in either quantitative assay (p=0.054) or the qualitative assay (p=0.06). A comparison of the ration (qualitative/quantitative) showed a statistical difference (p=0.016). It can be suggested from these results that the resistance to heparin demonstrated in heparin therapy patients is the result of a combination of factors associated with AT III. Administration of heparin decreases the available AT III and decreases its function. The combination of these two factors contributes to this resistance phenomenon.
No takes yet. Share an insight, caveat, or question.
Rivard et al. (1990) conducted an observational in Heparin resistance in patients undergoing coronary artery bypass grafting (n=30). Preoperative intravenous heparin therapy vs. No preoperative intravenous heparin therapy was evaluated on Antithrombin III qualitative-to-quantitative (activity-to-antigen level) ratio (p=0.016). Preoperative intravenous heparin therapy reduced the antithrombin III qualitative-to-quantitative activity ratio compared with no preoperative heparin in CABG patients.
Synapse has enriched 10 related papers. Consider them for comparative context: